A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL)  by Gribben, J.G. et al.
outcome in MM patients. Between January 2003 and September
2004, 13 MM patients received GM-CSF and IFN-	 therapy
following ASCT. IFN-	 was started within 120 days after ASCT at
a dose of 1 million units and increased as tolerated to 4 million
units subcutaneously 3  per week. GM-CSF was started at 125
g/m2day subcutaneously on the same days with IFN-	. The
combination therapy continued for 1 year, after which GM-CSF
was stopped. Ten patients receiving this combination therapy (me-
dian age, 61 years) were evaluable for analysis. Disease status at the
time of enrollment was complete remission in 1 patient, partial
remission in 4 patients, and very good partial remission in 5
patients. Six patients had stage III and 4 had stage II, with only 1
in renal failure. Median follow-up from last ASCT was 16 months.
Median duration of combination therapy was 7.5 months (range,
1–12 months). The median tolerated dose of IFN-	 was 4 million
units, although 2 patients had a permanent dose reduction to 2 or
3 million units due to ﬂu-like symptoms. None of the patients
dropped from the trial secondary to myelosuppression. Three
patients dropped out due to persistent ﬂu-like symptoms or ele-
vated liver function tests secondary to IFN-	, 2 patients dropped
out due to disease progression, and 1 patient had a GM-CSF dose
reduction due to leukocytosis. Median PLT count and ANC at 3
months were 136,000/L and 3800/L, respectively. One patient
required Procrit therapy. All patients received GM-CSF and
IFN-	 therapy for a minimum of 34 days. Two patients improved
to CR from PR and VGPR, 2 patients progressed, 5 patients
remained stable, and 1 patient was lost to follow-up. Using the
method of Kaplan and Meier, median PFS and OS for the whole
group have not been reached. In a previous analysis of 25 similar
patients who received a median of 8 months of IFN-	–only main-
tenance therapy (median tolerated dose of 3 million units), 10
patients had to discontinue therapy due to myelosuppression. In
conclusion, the addition of GM-CSF to IFN-	 is well tolerated
and is very effective in preventing IFN-induced myelosuppression.
It is too early to tell whether a survival beneﬁt will be realized.
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Background: T cells can be activated and expanded ex vivo using
the Xcellerate™ process, in which peripheral blood mononuclear
cells (PBMCs) are incubated with anti-CD3 and anti-CD28 anti-
body–coated magnetic beads (Xcyte™ Dynabeads). In an ongo-
ing trial of Xcellerated t cells in subjects with chronic lymphocytic
leukemia, marked and sustained reductions in lymphadenopathy
and splenomegaly were observed. This study is designed to deter-
mine whether similar effects can be observed in subjects with
indolent NHL. Methods: Subjects must have relapsed or refrac-
tory indolent NHL. PBMCs are collected by leukapheresis for the
Xcellerate™ process, and subjects subsequently receive 2 infusions
of 20–60  109 Xcellerated t cells separated by 6–8 weeks. Ap-
proximately 40 subjects will be treated. Results: Twenty subjects
have been enrolled. The median number of prior treatment regi-
mens was 3 (range, 1–4). Histological subtypes are small lympho-
cytic (n  9), follicular (n  5), mantle cell (n  4), and marginal
zone (n  2). Xcellerated t cells have been manufactured in 15
subjects to date, and 13 subjects have been treated. No related
serious adverse events have been reported to date. Follow-up is
available in 8 subjects through week 6. In these subjects, the
median number of cells infused was 39 109 (range, 33–39 109),
of which 98.9  0.2% were T cells (mean  SD). T-cell counts
increased from 728 56/mm3 before infusion to 1251 953/mm3
on day 28 (mean  SD). All 3 SLL subjects had marked reductions
in peripheral lymphadenopathy on physical examination, and 2 of
these patients also showed decreases on computed tomography
scan. However, the patients did not meet radiographic criteria for
response; 2 of them had bulky abdominal lymphadenopathy. A
bone marrow biopsy specimen obtained in 1 of the SLL subjects
revealed a decrease in leukemic involvement from 70% to 40% of
cellularity. In 2 subjects with follicular lymphoma, 1 had stable
disease radiographically and 1 had disease progression. Three sub-
jects with mantle cell lymphoma had progressive disease. Conclu-
sions: Xcellerated t cells can be manufactured in subjects with
indolent NHL. Treatment leads to signiﬁcant increases in T-cell
counts. Preliminary data suggest a reduction in peripheral lymph-
adenopathy and bone marrow involvement in SLL subjects. Data
on additional subjects will be presented.
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Background: Previous studies have demonstrated a correlation
between survival and lymphocyte recovery following autologous
transplantation in subjects with multiple myeloma and other ma-
lignancies. We initiated a trial in the transplantation setting to
evaluate the activity of T cells activated and expanded ex vivo with
the Xcellerate™ process, which uses anti-CD3 and anti-CD28
antibody–coated magnetic beads (Xcyte™ Dynabeads). Meth-
ods: After induction therapy, patients underwent leukapheresis to
collect peripheral blood mononuclear cells for the Xcellerate™
process. Patients then underwent stem cell mobilization and col-
lection, followed by high-dose melphalan (200 mg/m2). Three days
after peripheral blood stem cell infusion, subjects received 50–
100  109 Xcellerated T cells. Results: A total of 36 subjects were
treated. The median last follow-up visit is 360 days posttransplan-
tation (range, 180–630 days). A WaveBioreactor-based Xcellerate
III™ process, which was instituted in the last 18 subjects, resulted
in a 249-  90-fold (mean  SD) T-cell expansion. An average of
93.6  0.8  109 cells was infused, of which 97.6  4.0% were T
cells. There were no grade 3 or 4 acute infusional toxicities.
Median days of neutropenia and thrombocytopenia were 5 (range,
3–43 days) and 4.5 (range, 0–128 days), respectively. Median days
of hospitalization were 16 (range, 10–70 days). Lymphocyte re-
covery was rapid, with counts reaching  500/mm3 generally
within 1–2 days after T-cell infusion. Historically, lymphocyte
recovery to 500/mm3 usually does not occur for 3 or more weeks
posttransplantation. The rapid lymphocyte recovery included both
CD4 and CD8 T cells. The mean ( SEM) CD4 T-cell
count at 90 days posttransplantation was 1210  80/mm3, which is
signiﬁcantly higher than that for historical controls receiving the
same treatment regimen without Xcellerated T cells (198  72/
mm3). In 35 evaluable patients, preliminary results demonstrated
9% CRs, 51% VGPRs, 29% PRs, and 11% with PD, using the
M-protein at diagnosis as a reference. Conclusions: In multiple
myeloma subjects, administration of Xcellerated T cells after high-
dose chemotherapy and autologous stem cell transplantation leads
to rapid lymphocyte recovery. Most subjects achieve clinical re-
sponses in the autologous transplantation setting.
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Primary plasma cell leukemia (PPCL) is a rare subtype of mul-
tiple myeloma that follows a rapid clinical course and responds
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